Indivior PLC (INDV) Stock Forecast & Price Target

Indivior PLC has demonstrated robust growth in its Sublocade treatment, with the number of patients increasing by 8% year-over-year to approximately 171,500 in the third quarter of 2025, alongside a rise in prescribers by 11%. The company has revised its worldwide sales guidance for Sublocade to a range of $825 million to $845 million, indicating anticipated annual growth of approximately 10% at the midpoint. Additionally, Indivior's focus on expanding its market reach, particularly in the Medicaid and commercial patient segments, supports a positive outlook as the adoption of medication-assisted treatments (MATs) continues to rise in tandem with growing public awareness surrounding addiction treatment.

Indivior PLC faces a negative outlook primarily due to the anticipated decline in Suboxone revenue, which is expected to continue as a result of growing generic competition. Although growth in Sublocade is projected to offset some of this decline, it is still early in its commercial lifecycle, raising questions about its ability to fully compensate for the losses from Suboxone. Furthermore, the company’s significant selling, general, and administrative expenses (SG&A), projected at approximately 45% of revenue in 2026, indicate challenges in maintaining profitability amid revenue pressures.